SCHEMBL5412367

SCHEMBL5412367

CN(C(=O)Cn1c(=O)oc2ccc(-c3cccnc3)cc21)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TSPO P30536 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5424995 0.84 TSPO (0.59) TSPO
SCHEMBL5411082 0.83 TSPO (0.66) TSPO
Hydrochloric Acid SCHEMBL5417286 0.83 TSPO (0.76) TSPO
SCHEMBL5416616 0.80 TSPO (0.72) TSPO
Hydrochloric Acid SCHEMBL5413719 0.80 TSPO (0.66) TSPO
Hydrochloric Acid SCHEMBL5413721 0.80 TSPO (0.66) TSPO
SCHEMBL5411157 0.80 TSPO (0.69) TSPO
SCHEMBL5413554 0.80 TSPO (0.80) TSPO
SCHEMBL5425274 0.79 TSPO (0.67) TSPO
SCHEMBL5418860 0.79 TSPO (0.67) TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 — — US disclosed
EP-1719761-A1 NOVEL HETEROCYCLIC COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191447-A1 Novel heterocyclic compound OPRD1, GRIN3A, GRM3 TSPO 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback